This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Sigma Healthcare's Median PS Value or its related term are showing as below:
ASX:SIG'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52 Med: 0.85 Max: 1.95
Current: 1.95
During the past 13 years, the highest Price to Median PS Value of Sigma Healthcare was 1.95. The lowest was 0.52. And the median was 0.85.
ASX:SIG's Price-to-Median-PS-Value is ranked worse than 96.36% of 55
companies
in the Medical Distribution industry
Industry Median: 0.93
vs ASX:SIG: 1.95
Sigma Healthcare Median PS Value Historical Data
The historical data trend for Sigma Healthcare's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sigma Healthcare's Median PS Value
For the Medical Distribution subindustry, Sigma Healthcare's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigma Healthcare's Price-to-Median-PS-Value Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sigma Healthcare's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.1942.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sigma Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 was A$3.296.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigma Healthcare (ASX:SIG) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sigma Healthcare's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.245
/
0.64
=
1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigma Healthcare Median PS Value Related Terms
Thank you for viewing the detailed overview of Sigma Healthcare's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy. As a result, Sigma and its competitors are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:SIG has been successfully added to your 